Why the latest earnings and capital moves matter for ASP Isotopes

ASP Isotopes (ASPI) just reported first quarter results and paired them with fresh shelf registrations, combining revenue figures, ongoing losses, and potential future equity issuance into a single busy week for the stock.

At a share price of $5.55, ASP Isotopes has seen a 7.35% 1 day share price gain and a 6.73% 90 day share price return, while the 1 year total shareholder return is down 35.39% and the 3 year total shareholder return is very large. This suggests that momentum has been choppy as investors weigh recent earnings progress against dilution risk from the new shelf registrations.

If the recent earnings update has you thinking about where else growth stories might emerge in nuclear related supply chains, it could be worth scanning 88 nuclear energy infrastructure stocks

With first quarter revenue at US$4.18 million, an ongoing net loss of US$6.88 million, fresh shelf registrations, and a US$5.55 share price, is ASP Isotopes offering a mispriced growth story, or is the market already baking in future progress?

Preferred Price-to-Sales of 26x: Is it justified?

Based on the latest data, ASP Isotopes trades on a P/S ratio of 26x, which is very high next to both its Chemicals industry peers and its own estimated fair level.

The P/S ratio compares the company’s market value with its revenue. A higher multiple usually means investors are willing to pay more today for each dollar of current sales, often when strong future revenue growth is expected.

In ASP Isotopes’ case, the current P/S of 26x sits far above the US Chemicals industry average of 1.1x and the peer average of 1.5x. It is also well above the estimated fair P/S of 5.8x, a level the market could move towards if expectations or sentiment change.

Result: Price-to-Sales of 26x (OVERVALUED)

However, the development stage status, ongoing net loss of US$193.11 million, and potential dilution from new equity issuance could all challenge the current growth narrative.

Another view through the SWS DCF model

While the P/S of 26x already looks rich, the SWS DCF model points in the same direction. At a share price of $5.55, the stock is trading above an estimated future cash flow value of $1.75, which raises the question of how much optimism is already priced in.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ASP Isotopes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of high expectations, risks, and potential rewards feels finely balanced, now is a good time to review the details yourself and decide where you stand using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If ASP Isotopes has sharpened your thinking, now is the moment to widen your watchlist and size up other potential opportunities before the crowd moves on.

• Target quality at a discount by scanning 49 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect their strengths.
• Prioritise resilience by checking 66 resilient stocks with low risk scores that score well on stability for investors who want fewer surprises.
• Get ahead of the market by reviewing the screener containing 21 high quality undiscovered gems that combine solid fundamentals with relatively low visibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.